Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.40 |
| ▸ | HTR2A | P28223 | 9/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151929 | 0.84 | SLC6A4 (0.60) | NOTUMSLC6A4HTR2AKCNH2CYP19A1 | |
| SCHEMBL6151886 | 0.83 | HTR2A (0.43) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6151653 | 0.77 | HTR2A (0.60) | NOTUMSLC6A4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7237341 | 0.76 | HTR2A (0.59) | NOTUMSLC6A4HTR2AKCNH2 | |
| SCHEMBL5836789 | 0.75 | HTR2A (0.67) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5837924 | 0.73 | HTR2A (0.64) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5837170 | 0.73 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6151783 | 0.73 | SLC6A4 (0.40) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5836402 | 0.71 | HTR2A (0.48) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL6151864 | 0.71 | HTR2A (0.40) | SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1220831-B1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PROD INC (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | PFIZER INC | 2004-08-19 | — | — | US | claimed |
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | PFIZER INC. | 2003-07-10 | — | — | US | claimed |
| EP-1262196-A2 | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| EP-1260221-A2 | Combination treatment for depression and anxiety | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1220831-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | Pfizer Products Inc. (US) | 2002-07-10 | — | — | EP | claimed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | claimed |
| WO-2001027068-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-04-19 | — | — | WO | claimed |
| EP-1220831-B1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PROD INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| US-6596741-B2 | Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders. | PFIZER INC | 2003-07-22 | — | — | US | disclosed |
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | PFIZER INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1262196-A2 | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1260221-A2 | Combination treatment for depression and anxiety | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | OPRM1, OPRD1, OPRK1 | NOTUM 1542/4885SLC6A4 40/4885HTR2A 29/4885 |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | OPRM1, SLC6A2, OPRK1 | NOTUM 1460/4885SLC6A4 13/4885HTR2A 43/4885 |
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | SLC6A2, SLC6A3, SLC18A2 | NOTUM 1358/4885SLC6A4 6/4885HTR2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.